Cholera vaccination beneficial, post-outbreak

Researchers newly report evidence that vaccination against cholera can be beneficial even after an outbreak has begun. Rita Reyburn, Dr. Lorenz von Seidlein, Dr. John Clemens and colleagues at the International Vaccine Institute (IVI) in Seoul, Korea analyze the impact that vaccination could have had on recent outbreaks around the globe in "The case for reactive mass oral cholera vaccinations", and Drs. Dang Duc Anh and Anna Lena Lopez and colleagues at IVI and in Vietnam report on the impact of such "reactive" use of vaccine during an outbreak in "Use of oral cholera vaccines in an outbreak in Vietnam: a case control study". Both studies found a benefit to vaccination, and an accompanying editorial by Dr. Edward T. Ryan of Massachusetts General Hospital and Harvard University, "The Cholera Pandemic, Still with Us after Half a Century: Time to Rethink", comments on the significance of the works, especially in light of recent events in Haiti. The trio of publications appear January 25th in the open-access journal PLoS Neglected Tropical Diseases.

The recent outbreaks of cholera in Haiti, Pakistan, and Zimbabwe suggest that current global action plans against cholera are failing. "Although everyone agrees that the ultimate prevention and control of cholera will require provision of clean water and adequate sanitation to the world's population, the simple fact is that this will not be a reality for decades for the world's most impoverished, as well as for those affected by civil unrest and natural disasters," says Dr. Edward T. Ryan. "Less clear is the role that cholera vaccine could play once an outbreak has started. Classically, cholera would cause intensive and short outbreaks - by the time the vaccine was distributed, it was thought that the window of possible benefit would have passed. However, Vibrio cholerae, the causative agent of cholera, has undergone a number of mutations in the last few years, and is now associated with longer outbreaks, and more severe clinical disease, leading to higher case totality rates and increased drug resistance." Because of all these features, researchers and public health officials have taken a new look at the potential role of cholera vaccine to help control outbreaks, combined with attempts to provide clean water and improve sanitation.

Reyburn and colleagues model the effect of cholera vaccine once an outbreak has occurred using data from a number of recent outbreaks. The researchers modeled 50% and 75% vaccine coverage, with completion of vaccination ranging from "rapid" (10 weeks after an outbreak was first reported), to a "maximum" of completion of vaccination 33 weeks after an outbreak is first reported. They found that even delayed responses could have benefit, and their model neither included herd effect modifiers, nor the effect that vaccination could have on subsequent disease burden after the initial outbreak has waned into an endemic situation.

Anh and colleagues describe a case-control study of the reactive use of the Vietnamese killed cholera vaccine during a significant outbreak in Hanoi. Administration of 1 or 2 doses of the vaccine was found to provide approximately 76% protective efficacy.

These reports will contribute to the discussion on the role that cholera vaccine could play in both short and long-term response plans, including the response in Haiti.

The Cholera Pandemic, Still with Us after Half a Century: Time to Rethink

Financial Disclosure: The author has received no funding for this work.

Competing Interests: The author has declared that no competing interests exist.

PLEASE ADD THIS LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.plos.org/10.1371/journal.pntd.0001003. (link will go live upon embargo lift)

Citation: Ryan ET (2011) The Cholera Pandemic, Still with Us after Half a Century: Time to Rethink. PLoS Negl Trop Dis 5(1): e1003. doi:10.1371/journal.pntd.0001003

PRESS-ONLY PDF: http://www.plos.org/press/pntd-05-01-26-Ryan.pdf

Dr. Edward T. Ryan
Director, Tropical Medicine; Division of Infectious Diseases
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114 USA
Harvard University
etryan@partners.org

Financial Disclosure: The Bill and Melinda Gates Foundation (http://www.gatesfoundation.org) provided financial support through the Cholera Vaccine Initiative (CHOVI) program, administered by the International Vaccine Institute (IVI), Seoul, Republic of Korea. Current donors providing unrestricted support to the IVI include the Governments of Kuwait, Republic of Korea, and Sweden. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

PLEASE ADD THIS LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.plos.org/10.1371/journal.pntd.0001006. (link will go live upon embargo lift)

Citation: Anh DD, Lopez AL, Thiem VD, Grahek SL, Duong TN, et al. (2011) Use of Oral Cholera Vaccines in an Outbreak in Vietnam: A Case Control Study. PLoS Negl Trop Dis 5(1): e1006. doi:10.1371/journal.pntd.0001006

PRESS-ONLY PDF: http://www.plos.org/press/pntd-05-01-26-Lopez.pdf

Dr. Anna Lena Lopez
International Vaccine Institute
San 4-8 Nakseongdae-dong
Kwanak-gu
Seoul,
KOREA, REPUBLIC OF
annalenalopez@hotmail.com

Financial Disclosure: No funding was obtained or allocated for the preparation of this paper. R. Reyburn, J. Deen, A. Lopez, and J. Clemens are staff of the International Vaccine Institute, which promotes the use of vaccines, including oral cholera vaccines.

Competing Interests: The authors have declared that no competing interests exist.

PLEASE ADD THIS LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.plos.org/10.1371/journal.pntd.0000952. (link will go live upon embargo lift)

Citation: Reyburn R, Deen JL, Grais RF, Bhattacharya SK, Sur D, et al. (2011) The Case for Reactive Mass Oral Cholera Vaccinations. PLoS Negl Trop Dis 5(1): e952. doi:10.1371/journal.pntd.0000952

PRESS-ONLY PDF: http://www.plos.org/press/pntd-05-01-26-Reyburn.pdf

Contact:
Dr. Rita Reyburn
International Vaccine Institue
Chozan, Stonetown
Zanzibar, PO Box 3524
United Republic of Tanzania
rita_reyburn@hotmail.com

Disclaimer

This press release refers to upcoming articles in PLoS Neglected Tropical Diseases. The release is provided by the editor in conjunction with PLoS Neglected Tropical Diseases. Any opinions expressed in these releases or articles are the personal views of the journal staff and/or article contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the releases and articles and your use of such information.

PLoS Neglected Tropical Diseases (http://www.plosntds.org/) is a peer-reviewed, open-access journal devoted to the pathology, epidemiology, prevention, treatment, and control of the neglected tropical diseases, as well as public policy relevant to this group of diseases. All works published in PLoS Neglected Tropical Diseases are open access, which means that everything is immediately and freely available subject only to the condition that the original authorship and source are properly attributed. The Public Library of Science uses the Creative Commons Attribution License, and copyright is retained by the authors.

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org.